Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

We recently published 10 Stocks Jim Cramer Discussed Including His Palantir Deep Dive. Pfizer Inc. (NYSE:PFE) is one of the ...

The move, announced Thursday, escalates the competition between the two pharmaceutical giants for a critical advantage in the ...

On November 4, 2025, Pfizer reported third-quarter earnings showing a year-over-year decline in revenue to US$16.65 billion ...

Jim Cramer says Sempra (SRE) is a buy, supported by Wells Fargo's Overweight rating. Pfizer (PFE) and Dow (DOW) discussed.

Pfizer Inc. is rated a Buy with stable guidance, robust pipeline, strong free cash flows & appealing dividend yield. Learn ...

Pfizer Inc. is a global biopharmaceutical leader with a diversified product portfolio and significant scale, supported by annual revenue of $63.9 billion (TTM). Its extensive distribution network and ...

Better still, if interest rates drop, as they're generally expected to over the coming year, the interest income you'll get ...

Pfizer Inc. ( PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST ...

Pfizer Inc. (NYSE:PFE) is one of the Best Stocks to Buy for High Returns Heading into 2026. On October 27, Berenberg Bank ...

Pfizer (PFE) posted notable earnings growth, with net profit margins improving to 15.6%, a lift from the previous period’s 7%. Year-over-year, EPS growth soared 133.3%, marking a sharp reversal from ...

TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...